Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

29%

2 trials in Phase 3/4

Results Transparency

0 of 2 completed trials have results

Key Signals

3 recruiting

Enrollment Performance

Analytics

N/A

2(28.6%)

Phase 2

2(28.6%)

Phase 3

1(14.3%)

Phase 4

1(14.3%)

Phase 1

1(14.3%)

7Total

N/A(2)

Phase 2(2)

Phase 3(1)

Phase 4(1)

+1 more

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07198217Phase 2Recruiting

Real World Study of Platinum Containing Dual Drug Chemotherapy Followed by Large Fractionated Radiotherapy Combined withTislelizumab in Stage IIIB/C-IV Non-small Cell Lung Cancer Patient

Role: lead

NCT07085182Phase 2Recruiting

Tislelizumab Combined With sCRT in Stage IIIB/C-IV Non-Squamous Non-Small Cell Lung Cancer：A Prospective, Single-Arm, Phase II Study

Role: lead

NCT04720924Not ApplicableCompleted

AQCS for Detection of Early Cancer and Precancerous Lesions on Upper Gastrointestinal Tract

Role: collaborator

NCT04897126Phase 4Completed

Efficacy and Safety of Shexiang Baoxin Pill in Patients With Ischemia With Non-Obstructive Coronary Artery

Role: collaborator

NCT05794425Phase 1Recruiting

Clinical Study of UCB Combined With UC-MSCs in the Treatment of Bone Marrow Failure Disorders

Role: collaborator

NCT04305106Phase 3Unknown

Bevacizumab in Patients With Severe Covid-19

Role: collaborator

NCT04901130Not ApplicableUnknown

Impact of Real-time Automatic Quality Control System on Colorectal Adenoma Detection

Role: collaborator

All 7 trials loaded